

Comply, the Examiner states that claims 24 and 43 contain amino acid sequences that have not been entered into the sequence data base. This is not true.

The amino acid sequences in claims 24 and 43 are identical to SEQ ID NO: 28 and SEQ ID NO: 32 in the Sequence Listing filed March 29, 2001. In the claims the sequences are written in single letter code and in the Sequence Listing the sequences are written in triple letter code.

S A A P L V T A M C R S G N V S

Ser Ala Ala Pro Leu Val Thr Ala Met Cys Arg Ser Gly Asn Val Ser SEQ ID NO: 28

S A A P L V T A M C G S G N V S

Ser Ala Ala Pro Leu Val Thr Ala Met Cys Gly Ser Gly Asn Val Ser SEQ ID NO: 32

In light of the above, it is clear that no additional sequences need to be added to the Sequence Listing.


Applicant respectfully requests entrance of the above Amendment and consideration of the Remarks. Applicant further requests that since the filing of the last Sequence Listing on March 29, 2001 was almost a year ago, that a substantive Action be issued soon. Please charge any fees that may be associated with this matter, or credit any overpayments, to our Deposit Account No. 03-1721.

Respectfully submitted,

Dated: March 21, 2002

Karoline K. M. Shain Reg #
Brenda Hersbach Jarrell, Ph.D. 44,332
Reg. No.: 39,223

CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
Tel: (617) 248-5000
Fax: (617) 248-4000



VERSION WITH MARKING SHOWING CHANGES MADE

Claims 24 and 43 have been amended as follows:

24. (Amended) The method of claim 23, wherein the amino acid sequence of said dysfunctional signal peptide is SAAPLVTAMCRSGNVS (SEQ ID NO: 28) or SAAPLVTAMCGSGNVS (SEQ ID NO: 32).

43. (Amended) The N-terminal amino acid sequence of claim 41, wherein said amino acid sequence is SAAPLVTAMCRSGNVS (SEQ ID NO: 28) or SAAPLVTAMCGSGNVS (SEQ ID NO: 32).